NCT02891837: A trial that was reported late by Asklepion Pharmaceuticals, LLC
This trial has reported, although it was 414 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT02891837 |
|---|---|
| Title | A Phase III Double-Blind, Randomized, Placebo Controlled, Multi-Center Clinical Study to Evaluate the Efficacy and Safety of Intravenous L-citrulline for the Prevention of Clinical Sequelae of Acute Lung Injury Induced by Cardiopulmonary Bypass in Pediatric Subjects Undergoing Surgery for Congenital Heart Defects |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Aug. 31, 2016 |
| Completion date | June 30, 2019 |
| Required reporting date | June 29, 2020, midnight |
| Actual reporting date | Aug. 18, 2021 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 414 |